Form 4: DENTSPLY SIRONA Director Increases Holdings Through Dividend Reinvestment

DENTSPLY SIRONA Inc. Director Jonathan Jay Mazelsky increased his beneficial ownership of common stock and phantom stock through dividend reinvestment, as disclosed in a recent SEC Form 4 filing.

Summary

• Jonathan Jay Mazelsky, a Director of DENTSPLY SIRONA Inc. (XRAY), reported an increase in his beneficial ownership.
• On July 11, 2025, Mazelsky acquired 279.347 shares of common stock. These shares represent dividends on restricted stock units (RSUs) and are subject to the same vesting terms as the underlying awards, converting to common stock on a 1:1 basis.
• Additionally, on the same date, he acquired 75.0272 shares of phantom stock, which are comprised of accrued dividends. Each share of phantom stock is the economic equivalent of one share of common stock and becomes payable upon termination of service as a director.
• Following these transactions, Mazelsky directly beneficially owns 28,091.8 shares of common stock and 9,234.0374 shares of phantom stock.

Sentiment

Score: 6

Explanation: The filing indicates a routine increase in director holdings through dividend reinvestment, which is a neutral to slightly positive signal as it shows continued alignment of interests, but does not reflect a discretionary purchase.

Positives

• Director Jonathan Jay Mazelsky increased his beneficial ownership in DENTSPLY SIRONA Inc., indicating continued alignment of interests with shareholders.
• The acquisition of additional common stock and phantom stock through dividend reinvestment demonstrates a commitment to long-term holding and belief in the company's value.

Negatives

• No specific negative aspects are identified in this routine insider transaction filing.

Risks

• No specific risks are identified in this routine insider transaction filing.

Future Outlook

No specific future outlook or guidance is provided in this insider transaction filing.

Management Comments

• Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis.
• Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director.
• Comprised of phantom stock acquired as a result of accrued dividends.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, specifically dividend reinvestment, and does not provide broader industry context or trends. It reflects an individual director's compensation and investment activity within the dental products and technologies sector.

Comparison to Industry Standards

• Not applicable, as this document details a routine insider transaction (dividend reinvestment) and does not contain performance metrics or strategic initiatives that would allow for comparison to industry standards or specific comparable companies/projects.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment with management due to director's increased holdings, albeit through routine dividend reinvestment.

Next Steps

• No specific future actions or milestones are mentioned in this filing beyond the vesting terms of the RSUs and the payout of phantom stock upon termination of service.

Key Dates

Keywords

DENTSPLY SIRONA Inc., XRAY, Form 4, Insider Trading, Director Holdings, Common Stock, Phantom Stock, Dividend Reinvestment, Restricted Stock Units, Beneficial Ownership